On September 8-9, 2023, the 7th Immunogene and Cell Therapy Conference (IGC 2023) was held at the Beijing International Convention Center. The conference, themed "Innovation Drives Development, Integration Leads Translation," focused on the innovative research and development, as well as translation of new research, new technologies and new products in immune cell therapy (solid tumors, allogeneic universal, non-viral vectors), gene therapy, stem cell therapy, and more. Dr. Youjia Li, R&D Director of Leman Biotech, was invited to deliver a keynote speech. She shared the latest clinical research progress on metabolically enhanced CAR-T cell therapy, receiving high attention from the participating experts.
Dr. Youjia first introduced the remarkable effects observed in the early in vitro and animal model studies of Leman Biotech's Metabolically Enhanced CAR-T cell therapy. Subsequently, Dr. Li detailed the progress of Leman Biotech's first Metabolically Enhanced CAR-T cell therapy since the start of clinical research in February 2023, including recruitment, enrollment, infusion treatment, efficacy assessment, and long-term follow-up. She presented data from six patients who had already completed efficacy evaluations. All six patients achieved complete remission (CR) upon discharge, with the first patient having a follow-up of over six months and still maintaining CR status, and CAR-T persistence detected in the body. These results strongly suggest that Leman Biotech's Metabolically Enhanced CAR-T therapy holds promise for higher response rates and CR rates in patients.
In 2022, over 8 cellular and gene therapies were approved and marketed globally, along with more than 10 antibody drugs receiving initial approvals in Europe and the United States. In China, CAR-T has entered a period of rapid and differentiated competition. With continuous technological progress and iteration, it is foreseeable that there will be more breakthroughs in the future, bringing more personalized and differentiated treatment products for patients. As a biotechnology company focused on innovative metabolic immunotherapy drugs, Leman Biotech is committed to making its contribution, bringing more hope and choices for patients.
